Skycovione (redirect from GBP510)
on 5 September 2021. Retrieved 5 September 2021. "SK COVID-19 Vaccine "GBP510" CEPI "Wave2" (next-generation vaccine)ed as the first development support...
10 KB (764 words) - 11:54, 29 February 2024
On 9 November 2023, SK Bioscience submitted investigational new drug for GBP510 COVID-19 vaccine candidate to Korea Ministry of Food and Drug Safety, for...
21 KB (1,381 words) - 20:39, 16 May 2024
of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine Adjuvanted With AS03 (GBP510) in Adults Aged 18 Years and Older". ClinicalTrials.gov. 17 August 2021...
95 KB (18,965 words) - 15:46, 23 June 2024
by Icosavax, which began a Phase I/II clinical trial in June 2021, and GBP510 which is being developed by SK Bioscience and is already approved for a...
86 KB (8,570 words) - 07:03, 9 June 2024
(MV-SARS-CoV-2), Moderna (mRNA-1273), Novavax (NVX-CoV2373), SK bioscience (GBP510), and Hong Kong University. CEPI is an observer of the Global Research Collaboration...
29 KB (2,874 words) - 21:19, 22 July 2024